Gastrointestinal drugs

Side Effects of Drugs Annual

Volumn 35, Issue , 2014, Pages 633-658

  Blandizzi, Corrado ^a   Scarpignato, Carmelo ^a  

^a NONE

Author keywords

Activated charcoal; Adverse reactions; Alosetron; Aminosalicylates; Antacids; Antiemetics; Antispasmodic agents; Aprepitant; Bile acids; Bisacodyl; Bowel preparations; Bowel secretagogues; Cimetidine; Cisapride; Dexlansoprazole; Domperidone; Esomeprazole; Famotidine; Fosaprepitant; Granisetron; Helicobacter pylori eradication; Lansoprazole; Laxatives; Licorice; Linaclotide; Lubiprostone; Macrogols; Magnesium salts; Mesalazine; Metoclopramide; Neurokinin NK1 receptor antagonists; Omeprazole; Ondansetron; Palonosetron; Pantoprazole; Phosphates; Polyethylene glycol; Probiotics; Proton pump inhibitors; Rabeprazole; Racecadotril; Ranitidine; Senna; Sodium picosulfate; Sulfasalazine; Trimebutine; Ursodeoxycholic acid

Indexed keywords

EID: 84895140168     PISSN: 03786080     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62635-6.00036-X     Document Type: Chapter

References (141)

1. Kolnick L., Harris B.D., Choma D.P., Choma N.N. Hypercalcemia in pregnancy: a case of milk-alkali syndrome. J Gen Intern Med 2011, 26(8):939-942.
2. Kashouty R., Yono N., Al Samara M. Status epilepticus secondary to milk-alkali syndrome induced by hypercalcemia (oral antacids). Seizure 2011, 20(8):659-661.
3. Fernández-García M., Vázquez L., Hernández J.L. Calcium-alkali syndrome in post-surgical hypoparathyroidism. QJM 2012, 105(12):1209-1212.
4. Patel P., Song I., Borland J., Patel A., Lou Y., Chen S., Wajima T., Peppercorn A., Min S.S., Piscitelli S.C. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother 2011, 66(7):1567-1572.
5. Raphael B.P., Nurko S., Jiang H., Hart K., Kamin D.S., Jaksic T., Duggan C. Cisapride improves enteral tolerance in pediatric short-bowel syndrome with dysmotility. J Pediatr Gastroenterol Nutr 2011, 52:590-594.
6. Hondeghem L.M. Domperidone: limited benefits with significant risk for sudden cardiac death. J Cardiovasc Pharmacol 2013, 61:218-225.
7. Parkman H.P., Jacobs M.R., Mishra A., Hurdle J.A., Sachdeva P., Gaughan J.P., Krynetskiy E. Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects. Dig Dis Sci 2011, 56:115-124.
8. Roy-Desruisseaux J., Landry J., Bocti C., Tessier D., Hottin P., Trudel J.F. Domperidone-induced tardive dyskinesia and withdrawal psychosis in an elderly woman with dementia. Ann Pharmacother 2011, 45:e51.
9. Bonilla-Palomas J.L., López-López J.M., Moreno-Conde M., Gallego de la Sacristana A., Gámez-López A.L., Villar-Ráez A. Type I Brugada electrocardiogram pattern induced by metoclopramide. Europace 2011, 13:1353-1354.
10. Veerakul G., Nademanee K. Brugada syndrome: two decades of progress. Circ J 2012, 76:2713-2722.
11. Pasricha P.J., Pehlivanov N., Sugumar A., Jankovic J. Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006, 3:138-148.
12. Qiu L.M., Lim B.L. Case of acute akathisia from intravenous metoclopramide. Singapore Med J 2011, 52:e12-e14.
13. Supariwala A., Kant G., Jean R.E. Neuroleptic malignant syndrome with metoclopramide overdose coexisting with Clostridium difficile diarrhea. Intensive Care Med 2011, 37:1706-1708.
14. Surawski R.J., Quinn D.K. Metoclopramide and homicidal ideation: a case report and literature review. Psychosomatics 2011, 52:403-409.
15. Tura P., Erdur B., Aydin B., Turkcuer I., Parlak I. Slow infusion metoclopramide does not affect the improvement rate of nausea while reducing akathisia and sedation incidence. Emerg Med J 2012, 29:108-112.
16. Lewis J.H. The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies. Drug Saf 2011, 34(7):545-565.
17. Boccia R.V., Gordan L.N., Clark G., Howell J.D., Grunberg S.M. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011, 19:1609-1617. Sancuso Study Group.
18. Salvucci A.A., Squire B., Burdick M., Luoto M., Brazzel D., Vaezazizi R. Ondansetron is safe and effective for prehospital treatment of nausea and vomiting by paramedics. Prehosp Emerg Care 2011, 15:34-38.
19. Patel A., Mittal S., Manchanda S., Puliyel J.M. Ondansetron-induced dystonia, hypoglycemia, and seizures in a child. Ann Pharmacother 2011, 45:e7.
20. Tan J., Mehr S. Anaphylaxis to an ondansetron wafer. J Paediatr Child Health 2012, 48:543-544.
21. Gonullu G., Demircan S., Demirag M.K., Erdem D., Yucel I. Electrocardiographic findings of palonosetron in cancer patients. Support Care Cancer 2012, 20:1435-1439.
22. Jain A. Palonosetron-induced migraine-type headache. Can J Anaesth 2011, 58:230-231.
23. Grunberg S., Chua D., Maru A., Dinis J., DeVandry S., Boice J.A., Hardwick J.S., Beckford E., Taylor A., Carides A., Roila F., Herrstedt J. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011, 29(11):1495-1501.
24. Shayani S., Palmer J.M., Stiller T., Chan H., Keuylian S., Parker P., Thomas S., Pullarkat V., Nademanee A., Forman S.J., Nakamura R. Aprepitant (Emend) significantly increases sirolimus levels in patients undergoing allogeneic hematopoietic SCT. Bone Marrow Transplant 2012, 47(2):291-293.
25. Eom C.S., Jeon C.Y., Lim J.W., Cho E.G., Park S.M., Lee K.S. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ 2011, 183:310-319.
26. Böhmer G.M., Gleiter C.H., Mörike K., Nassr N., Walz A., Lahu G. No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine. J Clin Pharmacol 2011, 51(4):594-602.
27. Compoginis J.M., Gaspard D., Obaid A. Famotidine use and thrombocytopenia in the trauma patient. Am Surg 2011, 77:1580-1583.
28. Aouam K., Bouida W., Ben Fredj N., Chaabane A., Boubaker H., Boukef R., Boughattas N.A., Nouira S. Severe ranitidine-induced anaphylaxis: a case report and literature review. J Clin Pharm Ther 2012, 37(4):494-496.
29. Han T.Y., Jang W.S., Yu M., Lee H.K., Son S.J., Seo S.J. Anaphylactic reaction to ranitidine (Zantac ®). Int J Dermatol 2011, 50:1397-1399.
30. Córdoba S., Martínez-Morán C., García-Donoso C., Borbujo J., Gandolfo-Cano M. Non-occupational allergic contact dermatitis from pyridoxine hydrochloride and ranitidine hydrochloride. Dermatitis 2011, 22:236-237.
31. Terrin G., Passariello A., De Curtis M., Manguso F., Salvia G., Lega L., Messina F., Paludetto R., Canani R.B. Ranitidine is associated with infections, necrotizing enterocolitis, and fatal outcome in newborns. Pediatrics 2012, 129(1):e40-e45.
32. Anonymous Proton pump inhibitors. Reports of acute renal reactions, primarily interstitial nephritis. WHO Newslett 2011, 5:14.
33. Ngamruengphong S., Leontiadis G.I., Radhi S., Dentino A., Nugent K. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011, 106:1209-1218.
34. Anonymous Proton pump inhibitors (PPIs). Possible risk of Clostridium difficile-associated diarrhea (CDAD). WHO Newslett 2012, 2:13.
35. Trikudanathan G., Israel J., Cappa J., O'Sullivan D.M. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients-a systematic review and meta-analysis. Int J Clin Pract 2011, 65:674-678.
36. King R.N., Lager S.L. Incidence of Clostridium difficile infections in patients receiving antimicrobial and acid-suppression therapy. Pharmacotherapy 2011, 31:642-648.
37. Matok I., Levy A., Wiznitzer A., Uziel E., Koren G., Gorodischer R. The safety of fetal exposure to proton-pump inhibitors during pregnancy. Dig Dis Sci 2012, 57:699-705.
38. Anderka M., Mitchell A.A., Louik C., Werler M.M., Hernández-Diaz S., Rasmussen S.A. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 2012, 94:22-30. National Birth Defects Prevention Study.
39. Teichert M., van Noord C., Uitterlinden A.G., Hofman A., Buhre P.N., De Smet P.A., Straus S., Stricker B.H., Visser L.E. Proton pump inhibitors and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Haematol 2011, 153(3):379-385.
40. Maguire M., Franz T., Hains D.S. A clinically significant interaction between tacrolimus and multiple proton pump inhibitors in a kidney transplant recipient. Pediatr Transplant 2012, 16:E217-E220.
41. Milman S., Epstein E.J. Proton pump inhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. Endocr Pract 2011, 17:104-107.
42. Yildirim T., Yilmaz R., Baydar D.E., Kutlugun A.A., Aki T., Turgan C. Lansoprazole-induced acute allergic interstitial nephritis in a renal transplant recipient: a case report. Int Urol Nephrol 2012, 44:1903-1906.
43. Aksu K., Kurt E. Anaphylaxis to lansoprazole with tolerance to omeprazole. Allergol Immunopathol (Madr) 2012, 40:393-394.
44. Metz D.C., Pilmer B.L., Han C., Perez M.C. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol 2011, 106(11):1953-1960.
45. Langman M.J. Omeprazole. BMJ 1991, 303(6801):481-482.
46. Jianu C.S., Lange O.J., Viset T., Qvigstad G., Martinsen T.C., Fougner R., Kleveland P.M., Fossmark R., Hauso Ø., Waldum H.L. Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor. Scand J Gastroenterol 2012, 47(1):64-67.
47. Asajima H., Saito N., Ohmura Y., Ohmura K. Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide. Eur J Clin Pharmacol 2012, 68:331-333.
48. Tsubokura M., Miura Y., Itokawa T., Murata K., Takei N., Higaki T., Murashige N., Kami M., Komatsu T. Fatal dysrhythmia following initiation of lansoprazole during a long-term course of voriconazole. J Clin Pharmacol 2011, 51(10):1488-1490.
49. Negri A.L., Valle E.E. Hypomagnesaemia/hypokalemia associated with the use of esomeprazole. Curr Drug Saf 2011, 6:204-206. Erratum: 2013; 8: 75.
50. Mumoli N., Luschi R., Camaiti A., Cei M., Bagnoni G., Biondi A. Severe exfoliative dermatitis caused by esomeprazole. J Am Geriatr Soc 2011, 59:2377-2378.
51. Pérez-Ezquerra P.R., Morillas L.S., Martínez J.J., Fernández G.D., Gomez-Tembleque MdelP, Alvarez A.S., Sanz M.L. Anaphylaxis to omeprazole. Cross-reactivity with the other proton pump inhibitors. Allergol Immunopathol (Madr) 2011, 39:54.
52. Sanz-Gallén P., Nogué S., Herrera-Mozo I., Delclos G.L., Valero A. Occupational contact allergy to omeprazole and fluoxetine. Contact Dermatitis 2011, 65:118-119.
53. Harmsze A.M., de Boer A., Boot H., Deneer V.H., Heringa M., Mol P.G., Schalekamp T., Verduijn M.M., Verheugt F.W., le Comte M. Interactie tussen clopidogrel en protonpompremmers. [Interaction between clopidogrel and proton pump inhibitors]. Ned Tijdschr Geneeskd 2011, 155(28):A2442.
54. Canpolat U., Şahiner L., Aytemir K., Oto A. Allergic reaction to proton pump inhibitor: pantoprazole induced Kounis syndrome. Int J Cardiol 2012, 159:e27-e28.
55. Lai H.C., Hsu S.W., Lu C.H., Ma H.I., Cherng C.H., Hung N.K., Wu C.T. Anaphylaxis to pantoprazole during general anesthesia. J Anesth 2011, 25:606-608.
56. Neumark M., Ingber A., Levin M., Slodownik D. Occupational airborne contact dermatitis caused by pantoprazole. Contact Dermatitis 2011, 64:60-61.
57. Sánchez-Borges M., González-Aveledo L. Exfoliative erythrodermia induced by pantoprazole. Allergol Immunopathol (Madr) 2012, 40:194-195.
58. Quasdorff M., Mertens J., Dinter J., Steffen H.M. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. Ann Intern Med 2011, 155:405-407.
59. Sandig C., Flechtenmacher C., Stremmel W., Eisenbach C. Pantoprazole induces severe acute hepatitis. Z Gastroenterol 2011, 49:207-210.
60. Iwamoto T., Yabuki Y., Hara M., Morito T., Okaniwa A., Nemoto T., Ando M. Nihon Naika Gakkai Zasshi 2011, 100(5):1391-1393.
61. Wu D.C., Hsu P.I., Tseng H.H., Tsay F.W., Lai K.H., Kuo C.H., Wang S.W., Chen A. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore) 2011, 90:180-185.
62. Nadir I., Yonem O., Ozin Y., Kilic Z.M., Sezgin O. Comparison of two different treatment protocols in Helicobacter pylori eradication. South Med J 2011, 104:102-105.
63. Taş A., Akbal E., Koçak E., Köklü S. Moxifloxacin-tetracycline-lansoprazole triple therapy for first-line treatment of Helicobacter pylori infection: a prospective study. Helicobacter 2011, 16:52-54.
64. Choi K.H., Chung W.C., Lee K.M., Paik C.N., Kim E.J., Kang B.K., Oak J.H., Jung S.H. Efficacy of levofloxacin and rifaximin based quadruple therapy in Helicobacter pylori associated gastroduodenal disease: a double-blind, randomized controlled trial. J Korean Med Sci 2011, 26(6):785-790.
65. Dore M.P., Farina V., Cuccu M., Mameli L., Massarelli G., Graham D.Y. Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days. Helicobacter 2011, 16:295-300.
66. Ito Y., Hongo A., Kinoshita M., Tamaki H. Mechanism of anti-urease action by the anti-ulcer drug ecabet sodium. Biol Pharm Bull 1995, 18(6):850-853.
67. Shibata K., Ito Y., Hongo A., Yasoshima A., Endo T., Ohashi M. Bacterial activity of a new antiulcer agent, ecabet sodium, against Helicobacter pylori under acidic conditions. Antimicrob Agents Chemother 1995, 39(6):1295-1299.
68. Shibata K., Kasuga O., Yasoshima A., Matsushita T., Kawakami Y. Bactericidal effect of ecabet sodium on clarithromycin- and metronidazole-resistant clinical isolates of Helicobacter pylori. Jpn J Antibiot 1997, 50(6):525-531.
69. Hayashi S., Sugiyama T., Yachi A., Yokota K., Hirai Y., Oguma K., Fujii N. Effect of ecabet sodium on Helicobacter pylori adhesion to gastric epithelial cells. J Gastroenterol 1997, 32(5):593-597.
70. Sekine H., Ohara S., Iijima K., Kato K. Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment. Nihon Rinsho 1999, 57(1):116-120.
71. Hojo M., Miwa H., Nagahara A., Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001, 36(7):690-700.
72. Kono T., Nomura M., Kasai S., Kohgo Y. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 2001, 96(3):793-797.
73. Iizuka M., Itou H., Konno S., Shirasaka T., Horie Y., Shindo K., Watanabe S. Efficacy of ecabet sodium enema on steroid resistant or steroid dependent ulcerative colitis. Gut 2006, 55(10):1523.
74. Kagaya H., Kato M., Komatsu Y., Mizushima T., Sukegawa M., Nishikawa K., Hokari K., Takeda H., Sugiyama T., Asaka M. High-dose ecabet sodium improves the eradication rate of Helicobacter pylori in dual therapy with lansoprazole and amoxicillin. Aliment Pharmacol Ther 2000, 14(11):1523-1527.
75. Yang Kim H., Hahm K.B., Choi M.G., Rew J.S., Seol S.Y., Chun H.J., Lee O.Y., Hong W.S. Prospective multi-center trial for the efficacy of ecabet sodium on the relief of dyspepsia in Korean patients with chronic gastritis. J Clin Biochem Nutr 2007, 41(3):160-168.
76. Koizumi W., Tanabe S., Nakatani K., Ishido K., Nishimura K., Azuma M., Ae T., Sasaki T., Higuchi K., Katada C., Nakayama N., Saigenji K. Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). J Clin Pharm Ther 2010, 35(3):303-307.
77. Furuta T., Kato M., Sugimoto M., Sasaki M., Kamoshida T., Furukawa K., Inaba T., Tomita T., Shirai T., Ishii N., Nomura H., Konda Y., Asaka M. Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. Intern Med 2011, 50(5):369-374. Japan Gast Study Group.
78. Adachi K., Ishihara S., Hashimoto T., Hirakawa K., Ishimura N., Niigaki M., Kaji T., Kawamura A., Sato H., Fujishiro H., Hattori S., Watanabe M., Kinoshita Y. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment Pharmacol Ther 2001, 15(8):1187-1191.
79. Murata H., Kawano S., Tsuji S., Kamada T., Matsuzawa Y., Katsu K., Inoue K., Kobayashi K., Mitsufuji S., Bamba T., Kawasaki H., Kajiyama G., Umegaki E., Inoue M., Saito I. Combination therapy of ecabet sodium and cimetidine compared with cimetidine alone for gastric ulcer: prospective randomized multicenter study. J Gastroenterol Hepatol 2003, 18(9):1029-1033.
80. Koizumi W., Tnabe S., Imaizumi H., Kida M., Ohida M., Koshida Y., Mitomi H., Hosaka Y., Nagaba S., Sasaki T., Higuchi K., Saigenji K. Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of Helicobacter pylori: a prospective controlled study versus ranitidine. Hepato-Gastroenterology 2003, 50:577-581.
81. Lee J.H., Kim J.J., Hahm K.B., Lee D.H., Kim N., Kim S.K., Park J.J., Choi S.R., Lee J.H., Lee S.T., Lee E.H., Rhee J.C. Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial. World J Gastroenterol 2006, 12(17):2756-2761.
82. Kim H.W., Kim G.H., Cheong J.Y., Yang U.S., Park S.K., Song C.S., Kang D.H., Song G.A. H. pylori eradication: a randomized prospective study of triple therapy with or without ecabet sodium. World J Gastroenterol 2008, 14(6):908-912.
83. Chen C.F., You Z.H., Yang W.C., Lin C.C. Hypokalaemic paralysis with seemingly pH-neutralized blood gas: liquorice-induced mineralocorticoid effect superimposed on renal tubular acidosis. Acta Clin Belg 2011, 66(5):403.
84. Imtiaz K.E. Sweet root, bitter pill: liquorice-induced hyperaldosteronism. QJM 2011, 104(12):1093-1095.
85. Støving R.K., Lingqvist L.E., Bonde R.K., Andries A., Hansen M.H., Andersen M., Hørder K. Is glycyrrhizin sensitivity increased in anorexia nervosa and should licorice be avoided? Case report and review of the literature. Nutrition 2011, 27(7-8):855-858.
86. Nishiyama N., Takeshita M., Tanaka K., Miyao M., Mizuno Y. A case of severe hypokalemia caused by a Chinese herbal remedy (Yokukansan) in an 81-year-old woman with dementia. Nihon Ronen Igakkai Zasshi 2011, 48(5):553-557.
87. Imam M.H., Sinakos E., Gossard A.A., Kowdley K.V., Luketic V.A., Edwyn Harrison M., McCashland T., Befeler A.S., Harnois D., Jorgensen R., Petz J., Keach J., DeCook A.C., Enders F., Lindor K.D. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis. Aliment Pharmacol Ther 2011, 34(10):1185-1192.
88. Eaton J.E., Silveira M.G., Pardi D.S., Sinakos E., Kowdley K.V., Luketic V.A., Harrison M.E., McCashland T., Befeler A.S., Harnois D., Jorgensen R., Petz J., Lindor K.D. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol 2011, 106(9):1638-1645.
89. Kan W.C., Wang H.Y., Chien C.C., Tan C.K., Lin C.Y., Su S.B. Intermediate bioelectrolyte changes after phospho-soda or polyethylene glycol precolonoscopic laxatives in a population undergoing health examinations. Nephrol Dial Transplant 2012, 27:752-757.
90. Seo E.H., Kim T.O., Kim T.G., Joo H.R., Park M.J., Park J., Park S.H., Yang S.Y., Moon Y.S. Efficacy and tolerability of split-dose PEG compared with split-dose aqueous sodium-phosphate for outpatient colonoscopy: a randomized, controlled trial. Dig Dis Sci 2011, 56(10):2963-2971.
91. Lawrance I.C., Willert R.P., Murray K. Bowel cleansing for colonoscopy: prospective randomized assessment of efficacy and of induced mucosal abnormality with three preparation agents. Endoscopy 2011, 43:412-418.
92. Manukyan M.N., Tolan K., Severge U., Attaallah W., Kebudi A., Cingi A. Prospective randomized comparison of oral sodium phosphate and sennoside A+B calcium lavage for colonoscopy preparation. Surg Laparosc Endosc Percutan Tech 2011, 21:90-93.
93. Friedrich C., Richter E., Trommeshauser D., de Kruif S., van Iersel T., Mandel K., Gessner U. Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women. Drug Metab Pharmacokinet 2011, 26(5):458-464.
94. Maiello N., Del Giudice M.M., Capristo C., Decimo F., Santaniello F., Perrone L., Boner A. Severe allergic reaction to lactulose in a child with milk allergy. Ann Allergy Asthma Immunol 2011, 107:85.
95. Tatsumi H., Masuda Y., Imaizumi H., Kuroda H., Yoshida S., Kyan R., Goto K., Asai Y. A case of cardiopulmonary arrest caused by laxatives-induced hypermagnesemia in a patient with anorexia nervosa and chronic renal failure. J Anesth 2011, 25(6):935-938.
96. Nordt S.P., Chen J., Clark R.F. Severe hypermagnesemia after enteral administration of Epsom salts. Am J Health Syst Pharm 2011, 68:1384-1385.
97. Tatsuki M., Miyazawa R., Tomomasa T., Ishige T., Nakazawa T., Arakawa H. Serum magnesium concentration in children with functional constipation treated with magnesium oxide. World J Gastroenterol 2011, 17:779-783.
98. Jacobs W., Stas K., Coenegrachts J.L. Acute kidney injury after use of oral Fleet Phospho-soda as bowel preparation for colonoscopy. Acta Gastroenterol Belg 2011, 74:77-78.
99. Yang L.C., Arden D., Lee T.T., Mansuria S.M., Broach A.N., D'Ambrosio L., Guido R. Mechanical bowel preparation for gynecologic laparoscopy: a prospective randomized trial of oral sodium phosphate solution vs single sodium phosphate enema. J Minim Invasive Gynecol 2011, 18:149-156.
100. Chlumská A., Krekulová L., Mukeninabl P., Zámecník M. Mucosal changes after a polyethylene glycol bowel preparation for colonoscopy are less than those after sodium phosphate. Cesk Patol 2011, 47:130-131. nce.
101. Chlumskà A., Benes Z., Mukensnabl P., Zameanik M. Histologic findings after sodium phosphate bowel preparation for colonoscopy. Diagnostic pitfalls of colonoscopic biopsies. Cesk Patol 2010, 46:37-41.
102. Savitz J.A., Durning S.J. A rare case of anaphylaxis to bowel prep: a case report and review of the literature. Mil Med 2011, 176:944-945.
103. Hall C.C., DePiero A.D. Laxative-induced buttock dermatitis. J Emerg Med 2011, 40:212-213.
104. Vazquez Roque M., Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol 2011, 5:301-310.
105. Lembo A.J., Schneier H.A., Shiff S.J., Kurtz C.B., MacDougall J.E., Jia X.D., Shao J.Z., Lavins B.J., Currie M.G., Fitch D.A., Jeglinski B.I., Eng P., Fox S.M., Johnston J.M. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011, 365(6):527-536.
106. Schey R., Rao S.S. Lubiprostone for the treatment of adults with constipation and irritable bowel syndrome. Dig Dis Sci 2011, 56:1619-1625.
107. Lembo A.J., Johanson J.F., Parkman H.P., Rao S.S., Miner P.B., Ueno R. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011, 56:2639-2645.
108. Kevans D., Greene J., Galvin L., Morgan R., Murray F.E. Mesalazine-induced bronchiolitis obliterans organizing pneumonia (BOOP) in a patient with ulcerative colitis and primary sclerosing cholangitis. Inflamm Bowel Dis 2011, 17:E137-E138.
109. Shimodate Y., Takanashi K., Waga E., Fujita T., Katsuki S., Nomura M. Exacerbation of bloody diarrhea as a side effect of mesalamine treatment of active ulcerative colitis. Case Rep Gastroenterol 2011, 5:159-165.
110. Arai Y., Arihiro S., Ide D., Odagi I., Itagaki M., Komoike N., Nakao Y., Takakura K., Saruta M., Matsuoka M., Kato T., Tajiri H. Acute pancreatitis due to pH-dependent mesalazine that occurred in the course of ulcerative colitis. Case Rep Gastroenterol 2011, 5(3):610-616.
111. Al-Niaimi F., Lyon C. Mesalazine-induced photosensitivity. Eur J Dermatol 2011, 21:105-106.
112. Di Cesare A., Fidanza R., Riitano A., Fargnoli M.C., Peris K. Mesalazine-induced psoriasis in patients with inflammatory bowel diseases. Eur J Dermatol 2011, 21:784-785.
113. Linares V., Alonso V., Domingo J.L. Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity. Expert Opin Drug Saf 2011, 10(2):253-263.
114. Haroon M., Harney S. A case of severe pulmonary infiltration with eosinophilia (PIE) syndrome induced by sulphasalazine. Int J Rheum Dis 2012, 15(6):e150-e152.
115. DeMichele J., Rezaizadeh H., Goldstein J.I. Sulfasalazine crystalluria-induced anuric renal failure. Clin Gastroenterol Hepatol 2012, 10:A32.
116. Tremblay L., Pineton de Chambrun G., De Vroey B., Lavogiez C., Delaporte E., Colombel J.F., Cortot A. Stevens-Johnson syndrome with sulfasalazine treatment: report of two cases. J Crohns Colitis 2011, 5:457-460.
117. Daoulah A., Alqahtani A.A., Ocheltree S.R., Alhabib A., Ocheltree A.R. Acute myocardial infarction in a 56-year-old female patient treated with sulfasalazine. Am J Emerg Med 2012, 30(4):638.e13.
118. Hall S., Rindone J.P. A case of sulphasalazine potentiating the hypoprothombinemic effect of warfarin resulting in bleeding. J Clin Pharm Ther 2011, 36:246-248.
119. Lee S.Y., Kim M.Y., Kang S.Y., Song W.J., Kang H.R. A case of trimebutine-induced anaphylaxis. Allergol Int 2011, 60:555-556.
120. Eberlin M., Mück T., Michel M.C. A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril. Front Pharmacol 2012, 3:93.
121. O'Connor C.M., Gattis W.A., Gheorghiade M., Granger C.B., Gilbert J., McKenney J.M., Messineo F.C., Burnett J.C., Katz S.D., Elkayam U., Kasper E.K., Goldstein S., Cody R.J., Massie B.M. A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. Am Heart J 1999, 138(6Pt 1):1140-1148.
122. Lecomte J.M., Costentin J., Vlaiculescu A., Chaillet P., Marcais-Collado H., Llorens-Cortes C., Leboyer M., Schwartz J.C. Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor. J Pharmacol Exp Ther 1986, 237(3):937-944.
123. Baumer P., Akoué K., Bergmann J.F., Chaussade S., Nepveux P., Alexandre C.L., Schwartz J.C., Lecomte J.M. L'acetorphan, un puissant inhibiteur d'enkephalinase, ne modifié pas les temps de transit oro-caécal et colique chez l'homme sain. [Acetorphan, a potent enkephalinase inhibitor, does not modify orocecal and colonic transit times in healthy subjects.]. Gastroenterol Clin Biol 1989, 13(11):947-948.
124. Bergmann J.F., Chaussade S., Couturier D., Baumer P., Schwartz J.C., Lecomte J.M. Effects of acetorphan, an antidiarrhoeal enkephalinase inhibitor, on oro-caecal and colonic transit times in healthy volunteers. Aliment Pharmacol Ther 1992, 6(3):305-313.
125. Baumer P., Danquechin Dorval E., Bertrand J., Vetel J.M., Schwartz J.C., Lecomte J.M. Effects of acetorphan, an enkephalinase inhibitor, on experimental and acute diarrhoea. Gut 1992, 33(6):753-758.
126. Marçais-Collado H., Uchida G., Costentin J., Schwartz J.C., Lecomte J.M. Naloxone-reversible antidiarrheal effects of enkephalinase inhibitors. Eur J Pharmacol 1987, 144(2):125-132.
127. Emparanza Knörr J.I., Ozcoidi Erro I., Martínez Andueza M.C., Callén Blecua M.T., Alústiza Martínez E., Aseguinolaza Iparraguirre I. Revision sistematica sobre la eficacia de racecadotrilo en el tratamiento de la diarrea aguda. [Systematic review of the efficacy of racecadotril in the treatment of acute diarrhoea.]. An Pediatr (Barc) 2008, 69(5):432-438.
128. Lehert P., Chéron G., Calatayud G.A., Cézard J.P., Castrellón P.G., Garcia J.M., Santos M., Savitha M.R. Racecadotril for childhood gastroenteritis: an individual patient data meta-analysis. Dig Liver Dis 2011, 43(9):707-713.
129. Alam N.H., Ashraf H., Khan W.A., Karim M.M., Fuchs G.J. Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial. Gut 2003, 52(10):1419-1423.
130. Roge J., Baumer P., Berard H., Schwartz J.C., Lecomte J.M. The enkephalinase inhibitor, acetorphan, in acute diarrhoea. A double-blind, controlled clinical trial versus loperamide. Scand J Gastroenterol 1993, 28(4):352-354.
131. Vetel J.M., Berard H., Fretault N., Lecomte J.M. Comparison of racecadotril and loperamide in adults with acute diarrhoea. Aliment Pharmacol Ther 1999, 13(Suppl 6):21-26.
132. Turck D., Berard H., Fretault N., Lecomte J.M. Comparison of racecadotril and loperamide in children with acute diarrhoea. Aliment Pharmacol Ther 1999, 13(Suppl 6):27-32.
133. Prado D., Global Adult Racecadotril Study Group A multinational comparison of racecadotril and loperamide in the treatment of acute watery diarrhoea in adults. Scand J Gastroenterol 2002, 37(6):656-661.
134. Beaugerie L., Baumer P., Chaussade S., Berard H., Rozenbaum W., Pialoux G., Le Quintrec Y., Schwartz J.C., Lecomte J.M. Treatment of refractory diarrhoea in AIDS with acetorphan and octreotide: a randomized crossover study. Eur J Gastroenterol Hepatol 1996, 8(5):485-489.
135. Mehta S., Khandelwal P.D., Jain V.K., Sihag M. A comparative study of racecadotril and single dose octreotide as an anti-secretory agent in acute infective diarrhoea. J Assoc Physicians India 2012, 60:12-15.
136. Hamza H., Ben Khalifa H., Baumer P., Berard H., Lecomte J.M. Racecadotril versus placebo in the treatment of acute diarrhoea in adults. Aliment Pharmacol Ther 1999, 13(Suppl 6):15-19.
137. Salazar-Lindo E., Santisteban-Ponce J., Chea-Woo E., Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000, 343(7):463-467.
138. Cézard J.P., Duhamel J.F., Meyer M., Pharaon I., Bellaiche M., Maurage C., Ginies J.L., Vaillant J.M., Girardet J.P., Lamireau T., Poujol A., Morali A., Sarles J., Olives J.P., Whately-Smith C., Audrain S., Lecomte J.M. Efficacy and tolerability of racecadotril in acute diarrhea in children. Gastroenterology 2001, 120(4):799-805.
139. Nucera E., Schiavino D., Altomonte G., Buonomo A., Sabato V., Patriarca G. Hypersensitivity to racecadotril: a case report. Eur J Pediatr 2006, 165(6):418-419.
140. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H., Timmerman H.M., Nieuwenhuijs V.B., Bollen T.L., van Ramshorst B., Witteman B.J., Rosman C., Ploeg R.J., Brink M.A., Schaapherder A.F., Dejong C.H., Wahab P.J., van Laarhoven C.J., van der Harst E., van Eijck C.H., Cuesta M.A., Akkermans L.M., Gooszen H.G., Dutch Acute Pancreatitis Study Group Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371(9613):651-659.
141. Kim S.Y., Koo J.S., Hynun J.J., Jung S.W., Choung R.S., Yim H.J., Lee S.W., Choi J.H. Charcoal-induced pseudomelanosis ilei. Endoscopy 2011, 43(Suppl. 2):E380.